A Phase 3 interventional study of Immune Globulin Intravenous (Human), 10% Solution and Human albumin 0.25% in Alzheimer´s Disease, sponsored by Baxalta now part of Shire. Terminated at 69 sites in 8 countries. Open to participants aged 50 Years to 89 Years. Per ClinicalTrials.gov, last updated 2021-05-19.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 181st largest by enrollment of the 1,609 interventional ones that give a count, is one of 62 that started in 2012, is one of 188 in phase 3, and was the 491st registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,940 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 62 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 508 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,609 interventional studies, 160 across the 309 observational. Of the 1,378 that completed or were terminated, 590 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,940 have an industry lead sponsor. The 10 most frequent:
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Takeda has 7 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
165 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 165 to your calendar (.ics) → With an account.
Among the 1,940 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to provide evidence of efficacy and safety to support the development of IGIV, 10% as a treatment option for patients with mild to moderate Alzheimer´s Disease.
Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Immune Globulin Intravenous (Human), 10% Solution
Biological: Immune Globulin Intravenous (Human), 10% Solution
Biological: Human albumin 0.25%
Intravenous infusion every 2 weeks over 18 months
Also known as: IGIV, 10%
Intravenous infusion every 2 weeks over 18 months
Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog)
The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site. Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.
Time frame: Baseline to 9 Months (actual time frame)
Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory
The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner. Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.
Time frame: Baseline to 9 Months (actual time frame)
ADCS-Clinical Global Impression of Change (CGIC) at 18 Months
The ADCS-CGIC is a validated categorical measure of change in a participant's global clinical status between baseline and follow-up visits, based on interview of the participant and the caregiver by a skilled and experienced clinician who was blinded to treatment assignment. The ADCS-CGIC score is based on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening).
Time frame: Baseline to 9 Months (actual time frame)
Change From Baseline to Month 18 in Neuropsychiatric Inventory (NPI)
The NPI is a validated instrument used to assess behavioral psychopathology in AD; it evaluates the frequency and severity of 10 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.
Time frame: Baseline to 9 Months (actual time frame)
Change From Baseline to Month 18 in Volumetric Magnetic Resonance Imaging (MRI) Parameters: Rate of Whole Brain Atrophy and Ventricular Enlargement
Time frame: Baseline to 9 Months (actual time frame)
Change From Baseline to Month 18 in Logsdon Quality of Life in Alzheimer´s Disease (QOL-AD)
The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant´s quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52, with lower scores associated with a lower quality of life.
Time frame: Baseline to 9 Months (actual time frame)
Change From Baseline to Month 18 in Impact of Alzheimer´s Disease on Caregiver Questionnaire (IADCQ)
The IADCQ is a 12-item validated questionnaire that has been developed to measure the emotional, physical, and social impact of care giving on AD caregivers. Higher scores on the IADCQ are associated with a higher impact. IADCQ total score range: 0 (no impact) - 48 (greatest impact). Each item can be scored either 0 (Not at all), 1 (A little), 2 (Somewhat), 3 (A lot), or 4 (Extremely). As this is a 12-item scale, the minimum possible score is 0 and the maximum possible score is 4x12 = 48.
Time frame: Baseline to 9 Months (actual time frame)
Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs)
Time frame: Throughout the study period: 18 Months
Number of Participants Experiencing Any AEs and/or SAEs
Time frame: Throughout the study period: 18 Months
Number of Infusions Temporally Associated With AEs and/or SAEs
A temporal association was defined as an AE and/or SAE occurring during or within 72 hours of completion of an infusion, regardless of causality.
Time frame: During or within 72 hours of completion of an infusion
Number of Infusions Associated With AEs and/or SAEs Occurring During or Within 7 Days of Completion of an Infusion
Time frame: During or within 7 days of completion of an infusion
Number of Infusions Causally Associated With AEs and/or SAEs
Time frame: Throughout the study period: 18 Months
Number of Infusions Discontinued, Slowed, or Interrupted Due to an AE
Time frame: Throughout infusions, approximately 2-5 hours
Enrollment was conducted at 58 clinical sites worldwide.
| Milestone | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control |
|---|---|---|---|
| Started | 85 | 90 | 86 |
| Received treatment | 83 | 85 | 83 |
| Completed | 0 | 0 | 0 |
| Not completed | 85 | 90 | 86 |
| Withdrew: Withdrawal by subject | 6 | 2 | 3 |
| Withdrew: Adverse event | 5 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Study termination | 73 | 87 | 79 |
| Withdrew: Withdrawal by caregiver | 0 | 0 | 2 |
| Withdrew: Use of prohibited medication | 1 | 0 | 0 |
The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site. Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.
| Scores on a scale | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control |
|---|---|---|---|
| Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog) | 4.0 ± 6.44 | 4.4 ± 8.56 | 3.1 ± 4.28 |
The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner. Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.
| Scores on a scale | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control |
|---|---|---|---|
| Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory | -8.1 ± 7.36 | -5.0 ± 11.64 | -3.8 ± 9.26 |
The ADCS-CGIC is a validated categorical measure of change in a participant's global clinical status between baseline and follow-up visits, based on interview of the participant and the caregiver by a skilled and experienced clinician who was blinded to treatment assignment. The ADCS-CGIC score is based on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening).
| Scores on a scale | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control |
|---|---|---|---|
| ADCS-Clinical Global Impression of Change (CGIC) at 18 Months | 4.3 (3.7 to 4.8) | 4.4 (4.0 to 4.9) | 4.5 (4.1 to 5.0) |
The NPI is a validated instrument used to assess behavioral psychopathology in AD; it evaluates the frequency and severity of 10 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.
| Scores on a scale | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control |
|---|---|---|---|
| Change From Baseline to Month 18 in Neuropsychiatric Inventory (NPI) | 2.3 ± 5.76 | 3.8 ± 12.44 | 0.6 ± 5.68 |
| mm^3 | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control |
|---|---|---|---|
| Change From Baseline to Month 18 in Volumetric Magnetic Resonance Imaging (MRI) Parameters: Rate of Whole Brain Atrophy and Ventricular Enlargement | 0.00065 ± 0.00059 | 0.00057 ± 0.00070 | 0.00067 ± 0.00163 |
The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant´s quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52, with lower scores associated with a lower quality of life.
| Scores on a scale | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control |
|---|---|---|---|
| Change From Baseline to Month 18 in Logsdon Quality of Life in Alzheimer´s Disease (QOL-AD) | -0.1 ± 4.43 | 0.4 ± 3.68 | 0.1 ± 4.56 |
The IADCQ is a 12-item validated questionnaire that has been developed to measure the emotional, physical, and social impact of care giving on AD caregivers. Higher scores on the IADCQ are associated with a higher impact. IADCQ total score range: 0 (no impact) - 48 (greatest impact). Each item can be scored either 0 (Not at all), 1 (A little), 2 (Somewhat), 3 (A lot), or 4 (Extremely). As this is a 12-item scale, the minimum possible score is 0 and the maximum possible score is 4x12 = 48.
| Scores on a scale | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control |
|---|---|---|---|
| Change From Baseline to Month 18 in Impact of Alzheimer´s Disease on Caregiver Questionnaire (IADCQ) | 5.8 ± 4.13 | 1.9 ± 6.66 | 1.4 ± 5.97 |
| participants | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control |
|---|---|---|---|
| Participants with product-related AEs (incl SAEs) | 31 | 25 | 16 |
| Participants with product-related non-serious AEs | 30 | 25 | 16 |
| Participants with product-related SAEs | 1 | 0 | 1 |
| participants | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control |
|---|---|---|---|
| Participants with AEs (incl SAEs) | 57 | 54 | 49 |
| Participants with non-serious AEs | 55 | 53 | 48 |
| Participants with serious AEs (SAEs) | 5 | 7 | 7 |
A temporal association was defined as an AE and/or SAE occurring during or within 72 hours of completion of an infusion, regardless of causality.
| infusions | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control |
|---|---|---|---|
| Number of Infusions Temporally Associated With AEs and/or SAEs | 72 | 80 | 47 |
| infusions | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control |
|---|---|---|---|
| Number of Infusions Associated With AEs and/or SAEs Occurring During or Within 7 Days of Completion of an Infusion | 97 | 107 | 72 |
| infusions | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control |
|---|---|---|---|
| Number of Infusions Causally Associated With AEs and/or SAEs | 46 | 48 | 30 |
| infusions | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control |
|---|---|---|---|
| Number of Infusions Discontinued, Slowed, or Interrupted Due to an AE | 7 | 2 | 1 |
Collected over Throughout the study period. The study was terminated early and no subject completed 18 months of treatment as planned per protocol. The duration of exposure to the investigational product varied for each subject.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IGIV, 10% at High Dose (0.4 g/kg) | — | 5/83 (6%) | 30/83 (36.1%) |
| IGIV, 10% at Low Dose (0.2 g/kg) | — | 7/85 (8.2%) | 33/85 (38.8%) |
| Placebo Control | — | 7/83 (8.4%) | 30/83 (36.1%) |
| Event | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control |
|---|---|---|---|
| DehydrationMetabolism and nutrition disorders | 0/83 | 0/85 | 2/83 |
| Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/83 | 0/85 | 2/83 |
| Angina PectorisCardiac disorders | 1/83 | 0/85 | 1/83 |
| Food PoisoningGastrointestinal disorders | 0/83 | 0/85 | 1/83 |
| Gastroenteritis ViralInfections and infestations | 0/83 | 0/85 | 1/83 |
| Human EhrlichiosisInfections and infestations | 1/83 | 0/85 | 0/83 |
| PneumoniaInfections and infestations | 1/83 | 0/85 | 0/83 |
| Urinary Tract InfectionInfections and infestations | 1/83 | 0/85 | 0/83 |
| EncephalopathyNervous system disorders | 1/83 | 0/85 | 0/83 |
| HeadacheNervous system disorders | 1/83 | 0/85 | 0/83 |
| Event | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control |
|---|---|---|---|
| HeadacheNervous system disorders | 10/83 | 11/85 | 5/83 |
| DiarrhoeaGastrointestinal disorders | 1/83 | 0/85 | 10/83 |
| FatigueGeneral disorders | 5/83 | 10/85 | 6/83 |
| RashSkin and subcutaneous tissue disorders | 7/83 | 8/85 | 1/83 |
| Infusion Site ExtravasationGeneral disorders | 5/83 | 6/85 | 4/83 |
| Back PainMusculoskeletal and connective tissue disorders | 5/83 | 5/85 | 3/83 |
| NauseaGastrointestinal disorders | 5/83 | 5/85 | 3/83 |
| Upper Respiratory Tract InfectionInfections and infestations | 3/83 | 5/85 | 5/83 |
| NasopharyngitisInfections and infestations | 0/83 | 3/85 | 5/83 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 5/83 | 1/85 | 0/83 |
The baseline analysis population comprises treated subjects (=safety analysis set).
| Age, Continuous(years) | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control | Total |
|---|---|---|---|---|
| Mean | 72.0 ± 8.36 | 69.9 ± 8.59 | 70.6 ± 9.98 | 70.8 ± 9.01 |
| Sex: Female, Male(Participants) | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control | Total |
|---|---|---|---|---|
| Female | 43 | 37 | 52 | 132 |
| Male | 40 | 48 | 31 | 119 |
| Race (NIH/OMB)(Participants) | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 0 | 1 | 3 | 4 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 2 |
| Black or African American | 1 | 3 | 1 | 5 |
| White | 81 | 79 | 78 | 238 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | IGIV, 10% at High Dose (0.4 g/kg) | IGIV, 10% at Low Dose (0.2 g/kg) | Placebo Control | Total |
|---|---|---|---|---|
| United States | 66 | 67 | 66 | 199 |
| Canada | 8 | 7 | 7 | 22 |
| Spain | 3 | 5 | 3 | 11 |
| Belgium | 6 | 5 | 6 | 17 |
| Japan | 0 | 1 | 1 | 2 |
Ran from Jan 2012 to primary completion in Jul 2013, 17 months.
Results were first posted in Mar 2015, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous